Permeability enhancing effects of the alkylglycoside, octylglucoside, on insulin permeation across epithelial membrane in vitro

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 9, Issue 1, 2006, Pages 32-39

  Tirumalasetty, Phani Prasanth ^a,b   Eley, John G ^a,b  

^a Corium International Inc ^*  (United States)

^b IDAHO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; BALANCED SALT SOLUTION; CELL MARKER; GLYCOSIDE; INSULIN; OCTYL GLUCOSIDE; PENETRATION ENHANCING AGENT;

ARTICLE; ATTENUATION; CELL DAMAGE; CELL STRAIN CACO 2; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; ELECTRIC RESISTANCE; EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE PERMEABILITY; MODULATION; MONITORING; MONOLAYER CULTURE; TIGHT JUNCTION; TIME;

ABSORPTION; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DRUG INTERACTIONS; EPITHELIAL CELLS; GLUCOSIDES; GLYCOSIDES; HUMANS; INSULIN; TUMOR CELLS, CULTURED;

EID: 33646101022     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pauletti, GM., Gangwar, S, Knipp, T., Nerurkar,MM, Franklin W. Okumu, FW., Tamura, K., Siahaan, TJ. and Borchardt, R.T. Structural requirement for absorption of peptide drugs. Journal of controlled release, 41: 3-17, 1996.
2. Verhoef JC. Bodde HE. de Boer AG. Bouwstra JA. Junginger HE. Merkus FW. Breimer DD. Transport of peptide and protein drugs across biological membranes. [Review][95 refs] European Journal of Drug Metabolism & Pharmacokinetics. 15(2):83-93, 1990 Apr-Jun.
3. Heinemann, L., Pfützner, A. and Heise, T. Alternative routes of administration as an approach to improve insulin therapy: Update on dermal, oral, nasal and pulmonary insulin delivery 7 (14): 1327-1351, 2001 Sept.
4. Chein, YW. and Banga, AK. Potential developments in systemic delivery of insulin. Drug Dev. Ind. Pharm., 15: 1601-1617, 1989.
5. Houston, JB. and Wood, SG. Gastrointestinal absorption of drugs and other xenobiotics. in progress in drug metabolism, Vol. 4, Bridges, J.W. and Chasseaud, L.F., Eds., John Whiley and Sons, New York, 1980, Chapter 2.
6. Hoener, B., and Benet, LZ. Factors influencing drug absorption and drug availability. In: Modern Pharmaceutics, Banker, G.S. and Rodes, C.T., Eds., 1979, Chapter 4.
7. Hinchcliffe, M and Illum, L. Intranasal insulin delivery and therapy. Advanced Drug Delivery, 35: 199-234, 1999.
8. Gizurarson, S., and Bechgaard, E. Intranasal administration of insulin to humans. Diabetes Research Clinical Pract., 12 (2): 71-84, 1991 May.
9. Drejer, K. Pharmacokinetics of intranasally administered insulin with phospholipids as absorption enhancers. Diabetologia, 53(suppl. 1): A61, 1990.
10. Moses, AC., Gordon, GS., Carey MC. and Flier JS. Insulin administered intranasally as an insulin -bile salt aerosol - effectiveness and reproducibility in normal and diabetic subjects. Diabetes, 32 (11): 1040-1041, 1983 Nov.
11. Weber, N., and Bening, H. Metabolism of orally administered alkyl β-glucosides in the mouse. J. Nutr., 114 (2): 247-254, 1984 Feb.
12. Humphrey, MJ. The oral bioavailability of peptides and related drugs. In: Davis, S.S., Illum, L., and Tomlinson, E., eds., Delivery Systems for peptide drugs, New York, Plenum Press, 139-151.
13. Murakami, M., Kusanoi, Y., Takada, K and Muranishi, S. Assessment of enhancing ability of medium-chain alkyl saccharides as new absorption enhancers in rat rectum. International Journal of Pharmaceutics, 79:159-169, 1992 Feb.
14. Eley, J. and Tirumalasetty, P. In vitro assessment of alkylglycosides as permeability enhancers. AAPS PharmSciTech., 2(3):1-7 (article 12), 2001.
15. Verhoef, J., and Witter, A. In vivo fate of a behaviorally active ACTH 4-9 analog in rats after systemic administration. Pharmac. Biochem. Behav., 4 95): 583-590, 1976 May.
16. Shinkai, H., Toi, K., Kumashiro, I., Seto, Y., Fukuma, M., Dan, K.and Toyoshima,S. N-Acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. Journal of Med. Chem., 31: 2092-2097, 1988.
17. MacFadyen, RJ., Meredith, PA. and Elliott, HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships: an overview. Clinical pharmacokinetics, 25 (4): 274-282, 1993 Oct.
18. Gullikson, GW., Cline, WS., Lorenzsonn, V., Benz, L., Olsen, WA. and Bass P. Effect of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity. Gasteroenterology, 73 (3): 501-511, 1977 Sep.
19. Tsukamoto, T. and Nigam, SK. Role of tyrosine phosphorylation in the reassembly of occludine and other tight junction proteins. American Journal of Physiology, 276: F737-F750, 1999 May.
20. Shiyin, Y. Invitro permeability across Caco-2 cells can predict invivo absorption in man- fact or myth. Pharmaceutical research, 14(6): 763-766, 1997 June.
21. Delie, F. and Rubas, W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Critical Reviews in Therapeutic Drug Carrier Systems, 14(3): 221-286, 1997.
22. Claude, P. and Goodenough, D. Fracture faces of zonalae occludens from tight and leaky epithelia. Journal of Cell Biology, 58 (2): 390-400, 1973 Aug.
23. Madara, JL., Barenberg, D., Carlson, S., Effect of cytochalasin-D on occluding junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular pathway and junction charge selectivity. Journal of Cell Biology, 102(6): 2125-2136, 1986 June.
24. Lee, VHL., Yamamoto, A and Bhaskar, U. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Critical reviews in therapeutic drug carrier system, 8(2): 91-192, 1991.
25. Knipp, GT., Ho, NFH., Barsuhn, CL., and Borchardt, RT. Paracellular diffusion in Caco-2 monolayers: Effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. Journal of Pharmaceutical Sciences. 86(10): 1105-1110, 1997 Oct.